SynthesisNeuroImage. Clinical2019
Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis.
Synthesis in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Risk-taking in the human brain: An activation likelihood estimation meta-analysis of the balloon analog risk task (BART).Human brain mapping · 2022Pooled it
- The neuroscience of social feelings: mechanisms of adaptive social functioning.Neuroscience and biobehavioral reviews · 2021Pooled it
- Brainstem and Cerebellar Volume Loss and Associated Clinical Features in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Observational
- Midsagittal Midbrain Area and Midbrain-to-Pons-Ratio Cannot Distinguish Overlap Syndromes Between Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy.Clinical neuroradiology · 2026Article
- Hybrid Tau-PET/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET.European journal of nuclear medicine and molecular imaging · 2026Article
- Does Midbrain Atrophy Distinguish Progressive Supranuclear Palsy from Frontotemporal Dementia?Movement disorders clinical practice · 2025Article
- The dark sides of the brain: A systematic review and meta-analysis of functional neuroimaging studies on trait aggressionAggression and violent behavior · 2025Article
- Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Brainstem and cerebellar radiological findings in progressive supranuclear palsy.Brain communications · 2025Review
- TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers.Frontiers in cellular neuroscience · 2025Review
- Possible Impact of Peripheral Inflammatory Factors and Interleukin-1β (IL-1β) on Cognitive Functioning in Progressive Supranuclear Palsy-Richardson Syndrome (PSP-RS) and Progressive Supranuclear Palsy-Predominant Parkinsonism (PSP-P).International journal of molecular sciences · 2024Article
- Article
- Neurofilaments and progranulin are related to atrophy in frontotemporal lobar degeneration - A transdiagnostic study cross-validating atrophy and fluid biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Large-scale activation likelihood estimation meta-analysis of parkinsonian disorders.Brain communications · 2023Article
- Magnetic resonance imaging modalities aid in the differential diagnosis of atypical parkinsonian syndromes.Frontiers in neurology · 2023Review
- Observational
- Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes.Alzheimer's research & therapy · 2022Article
- Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies.Brain communications · 2022Article
- Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveProgressive supranuclear palsy (PSP) is an atypical parkinsonian syndrome characterized by vertical gaze palsy and postural instability. Midbrain atrophy is suggested as a hallmark, but it has not been validated systematically in whole-brain imaging.
methodsWe conducted whole-brain meta-analyses identifying disease-related atrophy in structural MRI. Eighteen studies were identified (N = 315 PSP, 393 controls) and separated into gray or white matter analyses (15/12). All patients were diagnosed according to the National Institute of Neurological Disorders and Stroke and the Society for PSP (NINDS-SPSP criteria, Litvan et al. (1996a)), which are now considered as PSP-Richardson syndrome (Höglinger et al., 2017). With overlay analyses, we double-validated two meta-analytical algorithms: anatomical likelihood estimation and seed-based D mapping. Additionally, we conducted region-of-interest effect size meta-analyses on radiological biomarkers and subtraction analyses differentiating PSP from Parkinson's disease.
resultsWhole brain meta-analyses revealed consistent gray matter atrophy in bilateral thalamus, anterior insulae, midbrain, and left caudate nucleus. White matter alterations were consistently detected in bilateral superior/middle cerebellar pedunculi, cerebral pedunculi, and midbrain atrophy. Region-of-interest meta-analyses demonstrated that midbrain metrics generally perform very well in distinguishing PSP from other parkinsonian syndromes with strong effect sizes. Subtraction analyses identified the midbrain as differentiating between PSP and Parkinson's disease.
conclusionsOur meta-analyses identify gray matter atrophy of the midbrain and white matter atrophy of the cerebral/cerebellar pedunculi and midbrain as characteristic for PSP. Results support the incorporation of structural MRI data, and particularly these structures, into the revised PSP diagnostic criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.